|
|
 |
 |
 |
 |
 |
|
| |
|
 |
| |
 |
|
| SmartDepot™ is a Peptron’s proprietary technology of manufacturing sustained release formulations using ultrasonic spray drying method. (Patent No. : KR0453273, KR0466637 Application No. : KR20030023130, JP20040187870 PCT: WO2005023224, WO2004112752). These formulations are consisted of biodegradable polymer and active pharmaceutical ingredients. The medicines that are manufactured by the SmartDepotTM release for 1 week to 6 months after 1 injection and have remedial value. |
|
|
| The technology can be applied for drug substances that are toxic or have to be injected very often because of their short half life in human body. The SmartDepotTM can increase not only remedial value but also convenience of patient, and minimize adverse effects. |
 |
|
|
|
|
| |
|
Peptron, Inc. has already marketed Luphere Depot®, 1 month formulation of leuprolide acetate, treating patients who have prostate cancer. We are in the progress of clinical trial of 3 month formulation of leuprolide acetate and 2 week formulation of exenatide acetate. Drugs for acromegaly, schizophrenia, and immunosuppression have also been developing. |
| |
 |
| |
 |
| |
 |
Maintenance of protein stability |
|
Biocompatible and bioabsorbable matrix |
|
Controlled in vivo release profile |
|
Complete release of protein |
|
|
|
|
 |
| |
|
| |
SusTein™ Technology |
| |
A preparation technology for solid protein-loaded microgranules which is continuously releasing proteins in vivo in the active state for several days.
(Patent No. : KR0452752
Application No. : US2003026844, EP1187602, US10/512.090
PCT : WO0178687, WO03094887
Trademark Resistration No. : 45-0008878000)
This technique is gleaned from nature's mechanism of stabilizing proteins by concentrating them in secretory granules and secreting them in soluble forms. SusTein™ formulation consists of two components, viz., condensed protein cores and encapsulating vehicle. Condensed protein cores are solid protein particles in which proteins are stabilized by complexation with sulfated polysaccharide at acidic pH. Condensed protein cores are coated with encapsulating vehicle, a sparingly water soluble matrix, which prevents burst release of protein and controls release rate of protein. |
| |
 |
| |
SmartRod™ Technology |
| |
|
|
 |
A preparation technology for a lipid implant which can continuously release protein in vivo as pharmaceutically active form after single subcutaneous injection.
(Patent No. : KR0486028
PCT : PCT/KR2005/001111
Trademark Registration No. :
40-05685480000) |
| Duration of in vivo release can be controlled in the range between several days to several months depending on the composition of lipids. In the SmartRod technique, we use biocompatible and bioabsorbable lipids as matrix components. Versatile in vivo release profiles with low initial release can be obtained by manipulating several essential manufacturing parameters. SmartRod™ is innovative technology in maintaining the stability of therapeutic proteins during manufacturing and in vivo releasing processes. |
|
|
| |
|
|
|
|
|
|
